Title : A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).

Pub. Date : 2022 Apr

PMID : 34824002






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Orteronel was administered at 300 mg BID; response rate was the primary endpoint. orteronel BH3 interacting domain death agonist Homo sapiens